What's new?

Sofinnova Partners closes €445M ($540M) oversubscribed late-stage healthcare crossover fund

The pioneering growth capital fund is the largest dedicated to biopharma and medtech companies seeking scale-up financing in Europe With over €2 billion under management, Sofinnova Partners continues its expansion across the entire value chain of life sciences investments, from seed to later-stage PARIS, France – M...

ABX464 Inhibits Replication of SARS-CoV-2 (COVID-19) in Reconstituted Human Respiratory Epithelium Model

ABX464 is the only drug candidate with a potential triple action for COVID-19 treatment: antiviral, anti-inflammatory and tissue repair

Genespire and SR-Tiget announce strategic alliance for the development of transformative gene therapies for genetic diseases and disclose collaboration focus

Pre-clinical data from SR-Tiget, included in the alliance with Genespire, to be presented at ASGCT 23rd Annual Meeting

1 ... 7 8 9